EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates - - BioPharm International

ADVERTISEMENT

EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates


EMD Serono, a subsidiary of Merck KGaA, and Mersana Therapeutics entered an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs). Mersana and EMD Serono will leverage Mersana's Fleximer technology to generate ADCs for multiple undisclosed targets.

"This new collaboration provides an exciting opportunity to expand our oncology drug discovery and development portfolio into the evolving ADC space," said Dr. Andree Blaukat, head of the Translational Innovation Platform Oncology at EMD Serono, in a press release.

Under the agreement, EMD Serono will provide monoclonal antibodies to Mersana, which will generate the Fleximer-ADCs and conduct drug discovery and preclinical development activities. EMD Serono will be responsible for clinical development and commercialization of any products under an exclusive license from Mersana. In addition to an upfront payment, Mersana is eligible to receive milestones plus royalties on worldwide net sales of products. Further financial details are not being disclosed.

Sources: EMD Serono

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines

Click here